NCT00251186终止2 期
Phase II Study of First-Line Capecitabine and Cetuximab for Treatment of Metastatic Colorectal Cancer in Elderly Patients and/or Those With Multiple Comorbidities Unable to Receive Chemotherapy Doublets
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Primary Objective
研究概览
简要总结
This is a Phase II clinical trial measuring the effectiveness of the combination of Capecitabine and cetuximab for first line treatment of colorectal cancer in elderly patients and/or those with multiple comorbidities unable to receive standard chemotherapy. This study will be open approximately 2-3 years. Approximately 36 patients will be enrolled on this study. The study will begin enrolling at The Cancer Institute of New Jersey, with 17 patients in the first group. If more than 4 responses are noted, the accrual will continue to 36 patients throughout CINJOG.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically proven diagnosis of locally extensive or metastatic colorectal cancer, not amenable to curative therapy.
- •No prior therapy for metastatic disease. Only 5-fluorouracil and leucovorin chemotherapy in the adjuvant setting will be allowed and the last treatment was given more then 6 months prior to metastatic disease development.
- •Patients with an ECOG performance score of 2 AND/OR Charlson comorbidity index of ³
- •Patients must be documented by the physician to be medically unable to tolerate oxaliplatin and/or irinotecan based chemotherapy.
- •Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as ³ 20 mm with conventional techniques or as ³10 mm with spiral CT scan.
- •Life expectancy of greater than 3 months.
- •Laboratory values showing adequate organ function prior to going on-study:
- •Absolute neutrophil count (ANC) ≥ 2.5 x 109/L
- •Platelets (PLT) 100 x 109/L
- •Hemoglobin 9g/dl (with or without transfusion)
- •Metabolic:Calculated creatinine clearance > 50 ml/min
- •Total Bilirubin £ 1.5 x Upper limit of normal (ULN)
- •AST £ 3 x ULN
- •Patient should be able to ingest oral medication.
- •Ability to understand and sign an approved informed consent.
排除标准
- •Patients with uncontrolled systemic disease other than the patient's colorectal cancer (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) for which the patient was admitted to the hospital within the prior month. Patients with stable respiratory, cardiac, hepatic or renal disease may participate subject to the guidelines in the eligibility criteria above.
- •Presence of dementia or delirium.
- •Unable to eat, dress, bathe or use the toilet independently. The patient must be able to ambulate independently unless limited by arthritis or musculoskeletal condition.
- •Patients with active gastritis within the last 3 months prior to study entry.
- •No synchronous or prior malignancy other than non-melanomatous skin cancer or insitu carcinoma of the cervix, unless disease free > 3 years.
- •Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •Pregnant women are ineligible as treatment involves unforeseeable risks to the participant and to the embryo or fetus. Women must either be not of child bearing potential or have a negative pregnancy test within 7 days of treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. Men and women must be willing to use adequate birth control measures to prevent contraception.
- •Inability to or unwillingness to comply with protocol defined treatment and assessments.
- •Prior therapy that specifically and directly targets the EGFR pathway.
- •Prior severe infusion reaction to a monoclonal antibody.
- •Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).
- •Patients ingesting herbal supplements, botanicals or vitamins in excess of recommended daily dose must be willing to stop their use, 1 week prior to study entry.
结局指标
主要结局
Primary Objective
To measure the response (CR/PR) for a novel chemotherapy/biologic combination-capecitabine/cetuximab for patients with metastatic colorectal cancer who are too fragile for more intensive chemotherapy doublet regimens.
次要结局
- Secondary Objectives
- To measure progression-free survival and document overall survival in this patient population.
- To assess the toxicity of capecitabine/cetuximab
- To describe the baseline quality of life and functional characteristics of elderly patients or those with multiple comorbidities enrolled in this study and assess the impact of disease and its treatment on such functional characteristics.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study to Compare Capecitabine + Bevacizumab Versus Capecitabine, Concomitantly With Radiotherapy as Neoadjuvant Treatment for Patients With Localized and Resectable Rectal CancerRectal CancerNCT01043484Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)90
已完成
2 期
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast CancerRecurrent Breast CancerStage IV Breast CancerNCT00077363National Cancer Institute (NCI)70
已完成
2 期
Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal CancerColorectal CancerNCT00215982H. Lee Moffitt Cancer Center and Research Institute24
已完成
2 期
Second Line Therapy in Advanced Biliary Tract CancerBiliary Tract CancerNCT01530503IRCCS San Raffaele52
撤回
2 期
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal CancerMetastatic Colorectal CancerNCT00954876Translational Genomics Research Institute